{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:32:16Z","timestamp":1792409536121,"version":"4.4.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL153262"],"award-info":[{"award-number":["R01HL153262"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL150891"],"award-info":[{"award-number":["R01HL150891"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fatty acid synthase (FAS) is predominantly expressed in the liver and adipose tissue. It plays vital roles in de novo synthesis of saturated fatty acids and regulates insulin sensitivity. We previously demonstrated that serum circulating FAS (cFAS) is a clinical biomarker for advanced atherosclerosis, and that it is conjugated to low-density lipoproteins (LDL). However, it remains unknown whether cFAS can directly impact atheroprogression. To investigate this, we evaluate whether cFAS impacts macrophage foam cell formation \u2013 an important cellular process leading to atheroprogression. Macrophages exposed to human serum containing high levels of cFAS show increased foam cell formation as compared to cells exposed to serum containing low levels of cFAS. This difference is not observed using serum containing either high or low LDL. Pharmacological inhibition of cFAS using Platensimycin (PTM) decreases foam cell formation in vitro. In\n                    <jats:italic>Apoe<\/jats:italic>\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice with normal FAS expression, administration of PTM over 16 weeks along with a high fat diet decreases cFAS activity and aortic atherosclerosis without affecting circulating total cholesterol. This effect is also observed in\n                    <jats:italic>Apoe<\/jats:italic>\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice with liver-specific knockout of hepatic\n                    <jats:italic>Fasn<\/jats:italic>\n                    . Reductions in aortic root plaque are associated with decreased macrophage infiltration. These findings demonstrate that cFAS plays an important role in arterial atheroprogression.\n                  <\/jats:p>","DOI":"10.1038\/s42003-025-07656-1","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:46:41Z","timestamp":1739962001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting fatty acid synthase reduces aortic atherosclerosis and inflammation"],"prefix":"10.1038","volume":"8","author":[{"given":"Rodrigo","family":"Meade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Belaygorod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batool","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fong-Fu","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Adak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Catlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0322-5910","authenticated-orcid":false,"given":"Mingzhou","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2888-4859","authenticated-orcid":false,"given":"Ma. Xenia G.","family":"Ilagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-1871","authenticated-orcid":false,"given":"Clay F.","family":"Semenkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-4527","authenticated-orcid":false,"given":"Mohamed A.","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"7656_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby, P. et al. Atherosclerosis. Nat. Rev. Dis. Prim. 5, 56 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"7656_CR2","doi-asserted-by":"publisher","first-page":"e721","DOI":"10.1016\/S2214-109X(20)30117-0","volume":"8","author":"P Song","year":"2020","unstructured":"Song, P. et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. Lancet Glob. Health 8, e721\u2013e729 (2020).","journal-title":"Lancet Glob. Health"},{"key":"7656_CR3","first-page":"109","volume":"60","author":"Centers for Disease C, Prevention","year":"2011","unstructured":"Centers for Disease C, Prevention. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999\u20132002 and 2005-200. MMWR Morb. Mortal. Wkly Rep. 60, 109\u2013114 (2011).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"7656_CR4","first-page":"452","volume":"15","author":"Z Wu","year":"2023","unstructured":"Wu, Z., Gao, L. & Lin, Z. Can proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors regress coronary atherosclerotic plaque? A systematic review and meta-analysis. Am. J. Transl. Res. 15, 452\u2013465 (2023).","journal-title":"Am. J. Transl. Res."},{"key":"7656_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267\u20131278 (2005).","journal-title":"Lancet"},{"key":"7656_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"M. P Bonaca","year":"2018","unstructured":"Bonaca, M. P. et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 137, 338\u2013350 (2018).","journal-title":"Circulation"},{"key":"7656_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.atherosclerosis.2014.09.026","volume":"237","author":"A. L Catapano","year":"2014","unstructured":"Catapano, A. L. et al. Combination therapy in dyslipidemia: where are we now? Atherosclerosis 237, 319\u2013335 (2014).","journal-title":"Atherosclerosis"},{"key":"7656_CR8","doi-asserted-by":"publisher","first-page":"e013851","DOI":"10.1136\/bmjopen-2016-013851","volume":"7","author":"M. D Danese","year":"2017","unstructured":"Danese, M. D. et al. Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open 7, e013851 (2017).","journal-title":"BMJ Open"},{"key":"7656_CR9","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"R. P Giugliano","year":"2017","unstructured":"Giugliano, R. P. et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 390, 1962\u20131971 (2017).","journal-title":"Lancet"},{"key":"7656_CR10","doi-asserted-by":"publisher","first-page":"e0272883","DOI":"10.1371\/journal.pone.0272883","volume":"18","author":"M Vrablik","year":"2023","unstructured":"Vrablik, M. et al. Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias. PLoS ONE18, e0272883 (2023).","journal-title":"PLoS ONE"},{"key":"7656_CR11","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.21037\/cdt.2017.04.04","volume":"7","author":"I. M Graham","year":"2017","unstructured":"Graham, I. M., Catapano, A. L. & Wong, N. D. Current guidelines on prevention with a focus on dyslipidemias. Cardiovasc. Diagn. Ther. 7, S4\u2013S10 (2017).","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"7656_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2022.100371","volume":"12","author":"M. E Makover","year":"2022","unstructured":"Makover, M. E., Shapiro, M. D. & Toth, P. P. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: a review of current practice and recommendations for improved effectiveness. Am. J. Prev. Cardiol. 12, 100371 (2022).","journal-title":"Am. J. Prev. Cardiol."},{"key":"7656_CR13","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1161\/CIR.0000000000000652","volume":"139","author":"M McClellan","year":"2019","unstructured":"McClellan, M., Brown, N., Califf, R. M. & Warner, J. J. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation 139, e44\u2013e54 (2019).","journal-title":"Circulation"},{"key":"7656_CR14","unstructured":"Writing Committee M, et al. AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 82 833-955 (2023)."},{"key":"7656_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/qjmed\/95.6.397","volume":"95","author":"U Ravnskov","year":"2002","unstructured":"Ravnskov, U. Is atherosclerosis caused by high cholesterol? QJM 95, 397\u2013403 (2002).","journal-title":"QJM"},{"key":"7656_CR16","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3390\/ijms23031308","volume":"23","author":"S Kotlyarov","year":"2022","unstructured":"Kotlyarov, S. & Kotlyarova, A. Involvement of fatty acids and their metabolites in the development of inflammation in atherosclerosis. Int. J. Mol. Sci. 23, 1308 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"7656_CR17","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1074\/jbc.RA118.001921","volume":"293","author":"R. G Carroll","year":"2018","unstructured":"Carroll, R. G. et al. An unexpected link between fatty acid synthase and cholesterol synthesis in proinflammatory macrophage activation. J. Biol. Chem. 293, 5509\u20135521 (2018).","journal-title":"J. Biol. Chem."},{"key":"7656_CR18","doi-asserted-by":"publisher","first-page":"15567","DOI":"10.1073\/pnas.0406901101","volume":"101","author":"B. Chakravarty","year":"2004","unstructured":"Chakravarty, B., Gu, Z., Chirala, S. S., Wakil, S. J. & Quiocho, F. A. Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain. Proc. Natl Acad. Sci. USA 101, 15567\u201315572 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"7656_CR19","unstructured":"Lehner R. Biochemistry of Lipids, Lipoproteins and Membranes 6th edn (Elsevier, 2016)."},{"key":"7656_CR20","first-page":"69","volume":"1","author":"H Liu","year":"2010","unstructured":"Liu, H., Liu, J. Y., Wu, X. & Zhang, J. T. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis\/prognosis marker. Int. J. Biochem. Mol. Biol. 1, 69\u201389 (2010).","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"7656_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98479-7","volume":"11","author":"S Tay","year":"2021","unstructured":"Tay, S. et al. Prevalence of elevated serum fatty acid synthase in chronic limb-threatening ischemia. Sci. Rep. 11, 19272 (2021).","journal-title":"Sci. Rep."},{"key":"7656_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.atherosclerosis.2019.05.016","volume":"287","author":"G. S De Silva","year":"2019","unstructured":"De Silva, G. S. et al. Circulating serum fatty acid synthase is elevated in patients with diabetes and carotid artery stenosis and is LDL-associated. Atherosclerosis 287, 38\u201345 (2019).","journal-title":"Atherosclerosis"},{"key":"7656_CR23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nature20117","volume":"539","author":"X Wei","year":"2016","unstructured":"Wei, X. et al. Fatty acid synthesis configures the plasma membrane for inflammation in diabetes. Nature 539, 294\u2013298 (2016).","journal-title":"Nature"},{"key":"7656_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13238-012-2025-6","volume":"3","author":"Y Yuan","year":"2012","unstructured":"Yuan, Y., Li, P. & Ye, J. Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis. Protein Cell 3, 173\u2013181 (2012).","journal-title":"Protein Cell"},{"key":"7656_CR25","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Boren","year":"2020","unstructured":"Boren, J. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 41, 2313\u20132330 (2020).","journal-title":"Eur. Heart J."},{"key":"7656_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1515\/CCLM.2008.118","volume":"46","author":"S Pilz","year":"2008","unstructured":"Pilz, S. & Marz, W. Free fatty acids as a cardiovascular risk factor. Clin. Chem. Lab. Med. 46, 429\u2013434 (2008).","journal-title":"Clin. Chem. Lab. Med."},{"key":"7656_CR27","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/00019501-199310000-00005","volume":"4","author":"A. R Sharrett","year":"1993","unstructured":"Sharrett, A. R. Serum cholesterol levels and atherosclerosis. Coron. Artery Dis. 4, 867\u2013870 (1993).","journal-title":"Coron. Artery Dis."},{"key":"7656_CR28","volume":"2012","author":"S Kovacic","year":"2012","unstructured":"Kovacic, S. & Bakran, M. Genetic susceptibility to atherosclerosis. Stroke Res. Treat. 2012, 362941 (2012).","journal-title":"Stroke Res. Treat."},{"key":"7656_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrcardio.2011.2","volume":"8","author":"A Brautbar","year":"2011","unstructured":"Brautbar, A. & Ballantyne, C. M. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat. Rev. Cardiol. 8, 253\u2013265 (2011).","journal-title":"Nat. Rev. Cardiol."},{"key":"7656_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_59_19","volume":"20","author":"R Hajar","year":"2019","unstructured":"Hajar, R. PCSK 9 inhibitors: a short history and a new era of lipid-lowering therapy. Heart Views 20, 74\u201375 (2019).","journal-title":"Heart Views"},{"key":"7656_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1475-2840-11-125","volume":"11","author":"A Tenenbaum","year":"2012","unstructured":"Tenenbaum, A. & Fisman, E. Z. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc. Diabetol. 11, 125 (2012).","journal-title":"Cardiovasc. Diabetol."},{"key":"7656_CR32","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","volume":"74","author":"D. K Arnett","year":"2019","unstructured":"Arnett, D. K. et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 74, e177\u2013e232 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"7656_CR33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.5551\/jat.RV17012","volume":"24","author":"T Nozue","year":"2017","unstructured":"Nozue, T. Lipid lowering therapy and circulating PCSK9 concentration. J. Atheroscler. Thromb. 24, 895\u2013907 (2017).","journal-title":"J. Atheroscler. Thromb."},{"key":"7656_CR34","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.5551\/jat.34660","volume":"23","author":"K Wakabayashi","year":"2016","unstructured":"Wakabayashi, K. et al. Efficacy of statin therapy in inducing coronary plaque regression in patients with low baseline cholesterol levels. J. Atheroscler. Thromb. 23, 1055\u20131066 (2016).","journal-title":"J. Atheroscler. Thromb."},{"key":"7656_CR35","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","volume":"147","author":"C. W Tsao","year":"2023","unstructured":"Tsao, C. W. et al. Heart Disease and Stroke Statistics-2023 update: a report from the American Heart Association. Circulation 147, e93\u2013e621 (2023).","journal-title":"Circulation"},{"key":"7656_CR36","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1161\/CIRCULATIONAHA.122.061010","volume":"147","author":"M. B Mortensen","year":"2023","unstructured":"Mortensen, M. B. et al. Low-density lipoprotein cholesterol is predominantly associated with atherosclerotic cardiovascular disease events in patients with evidence of coronary atherosclerosis: the Western Denmark Heart Registry. Circulation 147, 1053\u20131063 (2023).","journal-title":"Circulation"},{"key":"7656_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ahj.2008.08.010","volume":"157","author":"A Sachdeva","year":"2009","unstructured":"Sachdeva, A. et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am. Heart J. 157, 111\u20137 e2 (2009).","journal-title":"Am. Heart J."},{"key":"7656_CR38","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.3390\/molecules23102583","volume":"23","author":"C de Carvalho","year":"2018","unstructured":"de Carvalho, C. & Caramujo, M. J. The various roles of fatty acids. Molecules 23, 2583 (2018).","journal-title":"Molecules"},{"key":"7656_CR39","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3390\/nu11092022","volume":"11","author":"A. I. S. Sobczak","year":"2019","unstructured":"Sobczak, A. I. S., Blindauer, C. A. & Stewart, A. J. Changes in plasma free fatty acids associated with type-2 diabetes. Nutrients 11, 2022 (2019).","journal-title":"Nutrients"},{"key":"7656_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","volume":"51","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini, E., Sullivan, S. & Klein, S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51, 679\u2013689 (2010).","journal-title":"Hepatology"},{"key":"7656_CR41","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.3390\/ijms22136900","volume":"22","author":"A Hliwa","year":"2021","unstructured":"Hliwa, A., Ramos-Molina, B., Laski, D., Mika, A. & Sledzinski, T. The role of fatty acids in non-alcoholic fatty liver disease progression: an update. Int J. Mol. Sci. 22, 6900 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"7656_CR42","doi-asserted-by":"publisher","first-page":"23398","DOI":"10.1074\/jbc.M110.100321","volume":"285","author":"J. G Schneider","year":"2010","unstructured":"Schneider, J. G. et al. Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis. J. Biol. Chem. 285, 23398\u201323409 (2010).","journal-title":"J. Biol. Chem."},{"key":"7656_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112768","volume":"407","author":"L Tan","year":"2021","unstructured":"Tan, L., Lu, J., Liu, L. & Li, L. Fatty acid binding protein 3 deficiency limits atherosclerosis development via macrophage foam cell formation inhibition. Exp. Cell Res. 407, 112768 (2021).","journal-title":"Exp. Cell Res."},{"key":"7656_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.845942","volume":"9","author":"Y Gui","year":"2022","unstructured":"Gui, Y., Zheng, H. & Cao, R. Y. Foam Cells in Atherosclerosis: Novel Insights Into Its Origins, Consequences, and Molecular Mechanisms. Front Cardiovasc. Med. 9, 845942 (2022).","journal-title":"Front Cardiovasc. Med."},{"key":"7656_CR45","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.3390\/ijms21082716","volume":"21","author":"A. N Orekhov","year":"2020","unstructured":"Orekhov, A. N. et al. Signaling pathways potentially responsible for foam cell formation: cholesterol accumulation or inflammatory response-what is first? Int. J. Mol. Sci. 21, 2716 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"7656_CR46","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/CIRCULATIONAHA.113.005015","volume":"129","author":"S Allahverdian","year":"2014","unstructured":"Allahverdian, S., Chehroudi, A. C., McManus, B. M., Abraham, T. & Francis, G. A. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation 129, 1551\u20131559 (2014).","journal-title":"Circulation"},{"key":"7656_CR47","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1161\/CIRCRESAHA.115.304634","volume":"115","author":"S Feil","year":"2014","unstructured":"Feil, S. et al. Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circ. Res. 115, 662\u2013667 (2014).","journal-title":"Circ. Res."},{"key":"7656_CR48","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1073\/pnas.76.1.333","volume":"76","author":"J. L Goldstein","year":"1979","unstructured":"Goldstein, J. L., Ho, Y. K., Basu, S. K. & Brown, M. S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl.\\ Acad. Sci. USA 76, 333\u2013337 (1979).","journal-title":"Proc. Natl.\\ Acad. Sci. USA"},{"key":"7656_CR49","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/01.ATV.20.3.773","volume":"20","author":"N. L Jones","year":"2000","unstructured":"Jones, N. L., Reagan, J. W. & Willingham, M. C. The pathogenesis of foam cell formation: modified LDL stimulates uptake of co-incubated LDL via macropinocytosis. Arterioscle. Thromb. Vasc. Biol. 20, 773\u2013781 (2000).","journal-title":"Arterioscle. Thromb. Vasc. Biol."},{"key":"7656_CR50","doi-asserted-by":"publisher","first-page":"34573","DOI":"10.1074\/jbc.M205059200","volume":"277","author":"H. S Kruth","year":"2002","unstructured":"Kruth, H. S., Huang, W., Ishii, I. & Zhang, W. Y. Macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 277, 34573\u201334580 (2002).","journal-title":"J. Biol. Chem."},{"key":"7656_CR51","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1073\/pnas.0912059107","volume":"107","author":"J Ecker","year":"2010","unstructured":"Ecker, J. et al. Induction of fatty acid synthesis is a key requirement for phagocytic differentiation of human monocytes. Proc. Natl Acad. Sci. USA 107, 7817\u20137822 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"7656_CR52","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/89076","volume":"7","author":"L Makowski","year":"2001","unstructured":"Makowski, L. et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7, 699\u2013705 (2001).","journal-title":"Nat. Med."},{"key":"7656_CR53","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2019.10.002","volume":"291","author":"L Menegaut","year":"2019","unstructured":"Menegaut, L., Jalil, A., Thomas, C. & Masson, D. Macrophage fatty acid metabolism and atherosclerosis: the rise of PUFAs. Atherosclerosis 291, 52\u201361 (2019).","journal-title":"Atherosclerosis"},{"key":"7656_CR54","doi-asserted-by":"publisher","first-page":"12032","DOI":"10.3390\/ijms241512032","volume":"24","author":"E Vassiliou","year":"2023","unstructured":"Vassiliou, E. & Farias-Pereira, R. Impact of Lipid Metabolism on Macrophage Polarization: Implications for Inflammation and Tumor Immunity. Int. J. Mol. Sci. 24, 12032 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"7656_CR55","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1172\/JCI38388","volume":"120","author":"S Wueest","year":"2010","unstructured":"Wueest, S. et al. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. J. Clin. Invest 120, 191\u2013202 (2010).","journal-title":"J. Clin. Invest"},{"key":"7656_CR56","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cmet.2005.04.002","volume":"1","author":"M. V Chakravarthy","year":"2005","unstructured":"Chakravarthy, M. V. et al. \u201cNew\u201d hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 1, 309\u2013322 (2005).","journal-title":"Cell Metab."},{"key":"7656_CR57","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41392-022-01099-4","volume":"7","author":"D Cao","year":"2022","unstructured":"Cao, D. et al. Discovery of a mammalian FASN inhibitor against xenografts of non-small cell lung cancer and melanoma. Signal Transduct. Target. Ther. 7, 273 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"7656_CR58","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.3390\/molecules25173935","volume":"25","author":"C. W Fhu","year":"2020","unstructured":"Fhu, C. W. & Ali, A. Fatty Acid Synthase: An Emerging Target in Cancer. Molecules 25, 3935 (2020).","journal-title":"Molecules"},{"key":"7656_CR59","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/13543784.2018.1471132","volume":"27","author":"A Schcolnik-Cabrera","year":"2018","unstructured":"Schcolnik-Cabrera, A. et al. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy. Expert Opin. Investig. Drugs 27, 475\u2013489 (2018).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"7656_CR60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/biomedicines10010005","volume":"10","author":"M. Su","year":"2021","unstructured":"Su, M., Cao, D., Wang, Z., Duan, Y. & Huang, Y. Fatty acid synthase inhibitor platensimycin intervenes the development of nonalcoholic fatty liver disease in a mouse model. Biomedicines 10, 5 (2021).","journal-title":"Biomedicines"},{"key":"7656_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"G Falchook","year":"2021","unstructured":"Falchook, G. et al. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine 34, 100797 (2021).","journal-title":"EClinicalMedicine"},{"key":"7656_CR62","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/ja.2011.80","volume":"64","author":"E Martens","year":"2011","unstructured":"Martens, E. & Demain, A. L. Platensimycin and platencin: promising antibiotics for future application in human medicine. J. Antibiot.64, 705\u2013710 (2011).","journal-title":"J. Antibiot."},{"key":"7656_CR63","doi-asserted-by":"publisher","first-page":"e0164133","DOI":"10.1371\/journal.pone.0164133","volume":"11","author":"S. B Singh","year":"2016","unstructured":"Singh, S. B. et al. The fatty acid synthase inhibitor platensimycin improves insulin resistance without inducing liver steatosis in mice and monkeys. PLoS ONE 11, e0164133 (2016).","journal-title":"PLoS ONE"},{"key":"7656_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cmet.2004.11.004","volume":"1","author":"H Kuriyama","year":"2005","unstructured":"Kuriyama, H. et al. Compensatory increase in fatty acid synthesis in adipose tissue of mice with conditional deficiency of SCAP in liver. Cell Metab. 1, 41\u201351 (2005).","journal-title":"Cell Metab."},{"key":"7656_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19459-z","volume":"12","author":"M O\u2019Farrell","year":"2022","unstructured":"O\u2019Farrell, M. et al. FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. Sci. Rep. 12, 15661 (2022).","journal-title":"Sci. Rep."},{"key":"7656_CR66","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jcmgh.2019.02.001","volume":"7","author":"C. C Duwaerts","year":"2019","unstructured":"Duwaerts, C. C. & Maher, J. J. Macronutrients and the adipose-liver axis in obesity and fatty liver. Cell Mol. Gastroenterol. Hepatol. 7, 749\u2013761 (2019).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"7656_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.834199","volume":"9","author":"C Engel","year":"2022","unstructured":"Engel, C. et al. Altered Peroxisome Proliferator-Activated Receptor Alpha Signaling in Variably Diseased Peripheral Arterial Segments. Front. Cardiovasc. Med. 9, 834199 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"7656_CR68","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","volume":"44","author":"S. M Grundy","year":"2004","unstructured":"Grundy, S. M. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 44, 720\u2013732 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"7656_CR69","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0076-6879(81)72019-6","volume":"72","author":"A. H Ullman","year":"1981","unstructured":"Ullman, A. H. & White, H. B. 3rd Assay of fatty acid synthase using a bicyclic dione as substrate. Methods Enzymol. 72, 303\u2013306 (1981).","journal-title":"Methods Enzymol."},{"key":"7656_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15750","volume":"8","author":"I Sergin","year":"2017","unstructured":"Sergin, I. et al. Exploiting macrophage autophagy-lysosomal biogenesis as a therapy for atherosclerosis. Nat. Commun. 8, 15750 (2017).","journal-title":"Nat. Commun."},{"key":"7656_CR71","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0022-2275(20)32538-4","volume":"39","author":"C. F Semenkovich","year":"1998","unstructured":"Semenkovich, C. F., Coleman, T. & Daugherty, A. Effects of heterozygous lipoprotein lipase deficiency on diet-induced atherosclerosis in mice. J. Lipid Res. 39, 1141\u20131151 (1998).","journal-title":"J. Lipid Res."},{"key":"7656_CR72","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00018-022-04319-w","volume":"79","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2\/EP4 pathway. Cell Mol. Life Sci. 79, 303 (2022).","journal-title":"Cell Mol. Life Sci."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07656-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07656-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07656-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:48:38Z","timestamp":1739962118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07656-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7656"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-07656-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4139044\/v1","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.Z. is co-founder of AirSeal CardioVascular, Inc., a biomedical startup company that aims to clinically translate diagnostic approaches for individuals suffering from complications related to atherosclerotic cardiovascular disease. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}